[go: up one dir, main page]

KR940019726A - 종양괴사인자- 알파 뮤테인 - Google Patents

종양괴사인자- 알파 뮤테인 Download PDF

Info

Publication number
KR940019726A
KR940019726A KR1019930001751A KR930001751A KR940019726A KR 940019726 A KR940019726 A KR 940019726A KR 1019930001751 A KR1019930001751 A KR 1019930001751A KR 930001751 A KR930001751 A KR 930001751A KR 940019726 A KR940019726 A KR 940019726A
Authority
KR
South Korea
Prior art keywords
polypeptide
lysine
substitution
serine
arginine
Prior art date
Application number
KR1019930001751A
Other languages
English (en)
Other versions
KR970005042B1 (ko
Inventor
신항철
신남규
이인경
정호상
장승구
강성종
Original Assignee
조상진
주식회사 한일합섬
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 조상진, 주식회사 한일합섬 filed Critical 조상진
Priority to KR1019930001751A priority Critical patent/KR970005042B1/ko
Priority to GB9401977A priority patent/GB2275683B/en
Priority to FR9401347A priority patent/FR2701264B1/fr
Priority to JP6035386A priority patent/JP2837344B2/ja
Priority to DE4404124A priority patent/DE4404124C2/de
Publication of KR940019726A publication Critical patent/KR940019726A/ko
Priority to US08/538,875 priority patent/US5773582A/en
Priority to KR96067942A priority patent/KR970005043B1/ko
Application granted granted Critical
Publication of KR970005042B1 publication Critical patent/KR970005042B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 천연형 종양괴사인자-알파 혹은 기존의 뮤테인에 비해 세포독성이 증가된 종양괴사인자 뮤테인, 이를 코우딩하는 DNA, 이 DNA를 포함하는 벡터, 이 벡터에 의해 형질전환된 미생물 및 이를 이용한 종양괴사인자의 제조방법에 관한 것이다.

Description

종양괴사인자-알파 뮤테인
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 플라스미드 pGHH-TNF의 조립에 관한 개요를 나타낸 것이다.
제2도는 플라스미드 pT7-TNF의 조립에 관한 개요를 나타낸 것이다.

Claims (14)

  1. 아래 식[1]에 나타나 있는 아미노산 서열에서 최소한 4,5,6,7,8,9,10,38,39,40,41,52,53,54,56,85,86,87,88,127,128,129,156,157번 아미노산중 한개 이상의 아미노산이 다른 아미노산으로 치환된 폴리펩타이드, 및 그 폴리펩타이드의 아미노 말단으로부터 1개 이상 7개까지의 절단으로 만들어진 폴리펩타이드.
  2. 제1항의 아미노산 서열중에 다음의 치환중 하나 이상의 치환이 이루어진 폴리펩타이드.
    위치 4 : 세린을 아르지닌으로 치환
    위치 5 : 세린을 아르지닌으로 치환
    위치 6 :아르지닌을 알라닌으로 치환
    위치 7 : 트레오닌을 히스티딘 또는 라이신으로 치환
    위치 8 : 프롤린을 아르지닌으로 치환
    위치 9 : 세린을 라이신으로 치환
    위치 10 : 아스파라진산을 아르지닌으로 치환
    위치 38 : 알라닌을 아스파라진산으로 치환
    위치 39 : 아스파라진을 아스파라진산, 또는 라이신, 발린으로 치환
    위치 40 : 글라이신을 아스파라진산, 라이신, 또는 발린으로 치환
    위치 41 : 발린을 세린으로 치환
    위치 52 : 세린을 아이소류신, 글루타민산, 또는 라이신으로 치환
    위치 53 :글루타민산을 라이신, 또는 로이신으로 치환
    위치 54 : 글라이신을 아스파라진산, 또는 발린으로 치환
    위치 56 : 타이로신을 페닐알라닌, 또는 글루타민산으로 치환
    위치 85 : 발린을 글루타민산, 또는 아르지닌으로 치환
    위치 86 : 세린을 로이신, 라이신, 글루타민산, 또는 아스파라진산으로 치환
    위치 87 : 타이로신을 글루타민산, 또는 아르지닌으로 치환
    위치 88 : 글루타민을 글루타민산으로 치환
    위치 127 : 글루타민산을 알라닌, 발린, 또는 라이신으로 치환
    위치 128 : 라이신을 알라닌, 발린, 또는 글루타민산으로 치환
    위치 129 : 글라이신을 글루타민산, 라이신, 또는 발린으로 치환
    위치 156 : 알라닌을 아스파라진산으로 치환
    위치 157 : 로이신을 페닐알라닌으로 치환.
  3. 제2항에 있어서, 위치 4와 위치 5의 세린을 각각 아르지닌으로 치환하고 아미노 말단으로부터 4개의 절단으로 만들어진 폴리펩타이드.
  4. 제2항에 있어서, 위치 8,9,10,157의 프롤린, 세린, 아스파라진산, 로이신을 아르지닌, 라이신, 아르지닌, 페닐알라닌으로 각각 치환하고 아미노 말단으로부터 7개의 절단으로 만들어진 폴리펩타이드.
  5. 제2항에 있어서, 위치 52,56의 세린, 타이로신을 아이소류신, 페닐알라닌으로 각각 치환하고 아미노말단으로부터 7개의 절단으로 만들어진 폴리펩타이드.
  6. 제2항에 있어서, 위치 52,56,156,157의 세린, 타이로신, 알라닌, 로이신을 아이소류신, 페닐알라닌, 아스파라진산, 페닐알라닌으로 각각 치환하고 아미노 말단으로부터 7개의 절단으로 만들어진 폴리펩타이드.
  7. 제1항 내지 제6항중 어느 한 항에 있어서, 메티오닌이 아미노산 서열이 아미노 말단에 부가된 폴리펩타이드.
  8. 제1항 내지 제7항중 어느 한 항에 폴리펩타이드를 코우딩하는 DNA 염기 서열.
  9. 제8항의 DNA 염기 서열을 포함하는 벡터.
  10. 제9항의 벡터에 의해 형질전환된 미생물.
  11. 제10항에 있어서, 형질전환된 대장균(E. coli).
  12. 제10항 또는 제11항의 미생물을 배양하여 그 배양물로부터 폴리펩타이드를 분리하여 제1항 내지 제7항중 어느 한 항의 폴리펩타이드를 제조하는 방법.
  13. 제1항 내지 제7항중 어느 한 항의 폴리펩타이드 및 약학적으로 허용되는 담체를 함유하는 약학적 조성물.
  14. 제13항에 있어서, 제12항의 방법에 의해 제조된 폴리펩타이드 및 약학적으로 허용되는 담체를 함유하는 약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930001751A 1993-02-09 1993-02-09 종양괴사인자-알파 뮤테인 KR970005042B1 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR1019930001751A KR970005042B1 (ko) 1993-02-09 1993-02-09 종양괴사인자-알파 뮤테인
GB9401977A GB2275683B (en) 1993-02-09 1994-02-02 Tumor necrosis factor muteins
FR9401347A FR2701264B1 (fr) 1993-02-09 1994-02-07 Muteines de facteur de necrose tumorale.
JP6035386A JP2837344B2 (ja) 1993-02-09 1994-02-08 腫瘍壊死因子ミュテイン、その製法及び前記ミュテインをコードするポリヌクレオチド
DE4404124A DE4404124C2 (de) 1993-02-09 1994-02-09 TNF-Muteine, kodierendes Polynucleotid, Vektor, Mikroorganismus, Verfahren zur Herstellung der TNF-Muteine und TNF-Muteine enthaltende pharmazeutische Zusammensetzung
US08/538,875 US5773582A (en) 1993-02-09 1995-10-04 Tumor necrosis factor muteins
KR96067942A KR970005043B1 (en) 1993-02-09 1996-12-19 Tumor necrosis factor alpha muteins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930001751A KR970005042B1 (ko) 1993-02-09 1993-02-09 종양괴사인자-알파 뮤테인

Publications (2)

Publication Number Publication Date
KR940019726A true KR940019726A (ko) 1994-09-14
KR970005042B1 KR970005042B1 (ko) 1997-04-11

Family

ID=19350593

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019930001751A KR970005042B1 (ko) 1993-02-09 1993-02-09 종양괴사인자-알파 뮤테인
KR96067942A KR970005043B1 (en) 1993-02-09 1996-12-19 Tumor necrosis factor alpha muteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR96067942A KR970005043B1 (en) 1993-02-09 1996-12-19 Tumor necrosis factor alpha muteins

Country Status (6)

Country Link
US (1) US5773582A (ko)
JP (1) JP2837344B2 (ko)
KR (2) KR970005042B1 (ko)
DE (1) DE4404124C2 (ko)
FR (1) FR2701264B1 (ko)
GB (1) GB2275683B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE342729T1 (de) * 1997-01-15 2006-11-15 Phoenix Pharmacologics Inc Modifizierter tumor-nekrosefaktor
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7056695B2 (en) * 2000-03-02 2006-06-06 Xencor TNF-α variants
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7101974B2 (en) * 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7179891B2 (en) * 2002-03-25 2007-02-20 Tadanori Mayumi Physiologically active complex
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
WO2006074451A2 (en) * 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
US20100284962A1 (en) * 2009-05-06 2010-11-11 Oncopharmacologics, Inc. Modified tumor necrosis factor-beta
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57140725A (en) * 1981-12-28 1982-08-31 Dainippon Pharmaceut Co Ltd Physiologically active substance having carcinostatic action
JPS58141785A (ja) * 1982-02-16 1983-08-23 Nippon Shinyaku Co Ltd 抗腫瘍物質の製法
DE3582183D1 (de) * 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
GR851626B (ko) * 1984-07-05 1985-11-26 Genentech Inc
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
EP0205038A1 (en) * 1985-05-29 1986-12-17 Suntory Limited Polypeptide, process for preparing it, microorganism and pharmaceutical use
EP0251037B1 (en) * 1986-06-20 1994-06-15 Dainippon Pharmaceutical Co., Ltd. Novel human TNF polypeptide mutants and DNAs encoding said mutants
JPS63160598A (ja) * 1986-12-25 1988-07-04 Teijin Ltd 新規生理活性ポリペプチド
WO1988006625A2 (en) * 1987-02-26 1988-09-07 Cetus Corporation Arginine-depleted human tumor necrosis factor
JPH0797997B2 (ja) * 1988-04-28 1995-10-25 帝人株式会社 新規生理活性ポリペプチド
JPH0822239B2 (ja) * 1988-07-07 1996-03-06 株式会社蛋白工学研究所 変異ヒト腫傷壊死因子
US5262309A (en) * 1988-09-22 1993-11-16 Teijin Limited Terminal modifications of tumor necrosis factor
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
JPH02177896A (ja) * 1988-12-28 1990-07-10 Teijin Ltd 新規生理活性ポリペプチド
JPH0368600A (ja) * 1989-08-08 1991-03-25 Teijin Ltd 生理活性ポリペプチドの回収方法
JP2685608B2 (ja) * 1989-12-08 1997-12-03 帝人株式会社 新規生理活性ポリペプチド
JPH05255393A (ja) * 1990-09-21 1993-10-05 Ishihara Sangyo Kaisha Ltd ポリペプチド
JPH04327599A (ja) * 1991-04-25 1992-11-17 Teijin Ltd 新規生理活性ポリペプチド
SK376492A3 (en) * 1992-04-02 1995-06-07 Hoffmann La Roche Tnf - muteins and method of their production

Also Published As

Publication number Publication date
DE4404124C2 (de) 1999-12-30
KR970005043B1 (en) 1997-04-11
GB2275683A (en) 1994-09-07
FR2701264B1 (fr) 1995-08-04
GB9401977D0 (en) 1994-03-30
GB2275683B (en) 1997-03-26
JP2837344B2 (ja) 1998-12-16
US5773582A (en) 1998-06-30
FR2701264A1 (fr) 1994-08-12
JPH0770193A (ja) 1995-03-14
DE4404124A1 (de) 1994-08-11
KR970005042B1 (ko) 1997-04-11

Similar Documents

Publication Publication Date Title
KR940019726A (ko) 종양괴사인자- 알파 뮤테인
KR960031602A (ko) 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조 방법
DeLange et al. Histone III: III. SEQUENCE STUDIES ON THE CYANOGEN BROMIDE PEPTIDES; COMPLETE AMINO ACID SEQUENCE OF CALF THYMUS HISTONE III
Bec et al. Valyl-tRNA synthetase from rabbit liver: I. Purification as a heterotypic complex in association with elongation factor
KR920009848A (ko) 염기성 섬유아세포 성장인자 및 이의 생산방법
Bailey et al. Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules
O'Connell et al. The influence of flanking sequences on O-glycosylation
KR960700340A (ko) 안정한 살균/투과성-증가 단백질 생성물 및 그를 포함하는 제약학적 조성물(stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same)
AU2008281090B2 (en) Optimized purification process of recombinant growth factor protein
RU94015842A (ru) Пептидные кетоны, фармацевтическая композиция и способ ингибирования интерлейкин-1 протеазы
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
KR960700739A (ko) Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
KR880010130A (ko) 폴리 펩티드, dna 및 그의 용도
Aggarwal [33] Human lymphotoxin
RU2003104524A (ru) Masp-2, комплемент-связывающий фермент и его применение
BG101408A (en) Analogs of keratinocyte growth factor
CA2350327A1 (en) Methods of purifying recombinant human erythropoietin from cell culture supernatants
US6309859B1 (en) Method for removing N-terminal methionine
EP0845530A3 (en) Interferon gamma inducing factor
Browning et al. Disulfide scrambling of interleukin-2: HPLC resolution of the three possible isomers
DK0785950T3 (da) Keratinocyt vækstfaktoranaloger
Takao et al. Chemical characterization of recombinant human leukocyte interferon A using fast atom bombardment mass spectrometry.
ATE163651T1 (de) Neues menschliches, rekombinantes interferon gamma
Graber et al. Purification, characterisation and crystallisation of selenomethionyl recombinant human interleukin‐5 from Escherichia coli

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19930209

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19930209

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19960919

Patent event code: PE09021S01D

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19970308

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19970624

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19970912

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19970912

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 20000406

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20010403

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20020910

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20030905

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20040908

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20040908

Start annual number: 8

End annual number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee